GlassScriptPhysician profile
Yunus A Moosa
NPI 1548280464
$5,169.91
in general payments reported to CMS, 2019-2025
24 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $1,094 · 2021: $879 · 2022: $990 · 2023: $678 · 2024: $1,057 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Travel and Lodging: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.11 |
| Travel and Lodging | $512.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $1,024.37 | 2020 | |
| Penumbra, INC. | $574.14 | 2022-2024 | Indigo System |
| Abbott Laboratories | $541.12 | 2019-2025 | Jeti Peripheral Catheter, Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $527.31 | 2019-2024 | |
| Abiomed | $357.26 | 2020-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $311.14 | 2020-2025 | Lifevest |
| Shockwave Medical, INC | $302.85 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $191.85 | 2019-2024 | Recross, Pk Papyrus, Orsiro Mission |
| Merck Sharp & Dohme LLC | $179.18 | 2021-2023 | Verquvo |
| Edwards Lifesciences Corporation | $144.05 | 2023 | |
| Pfizer INC. | $124.47 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $119.12 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $104.09 | 2021-2022 | |
| Philips North America LLC | $99.66 | 2025 | Azurion 7 M20 |
| Amgen INC. | $90.43 | 2021-2023 | Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $85.50 | 2019 | |
| Inari Medical, INC. | $83.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $75.26 | 2022-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $67.60 | 2021-2023 | Farxiga |
| Bard Peripheral Vascular, INC. | $48.39 | 2020 | |
| Amarin Pharma, INC. | $39.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.04 | 2022 | |
| Cardiovascular Systems INC. | $22.09 | 2021 | |
| Scpharmaceuticals INC. | $17.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunus Moosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.